Gilead invented Veklury, building on more than a decade of research and experimentation.
Global operations 3.5 patch update#
Gilead continues to collaborate with global health authorities, government agencies, healthcare systems, academic institutions, non-profit organizations, and individual researchers and clinicians to share and update information and to bring the full weight of our science to help end this pandemic. EUA Information for hospitalized pediatric patients <12 years of age weighing at least 3.5 kg or weighing 3.5 kg to <40 kg For more information about the use of Veklury in the United States, including important safety information, please refer to the following links:
For the treatment of COVID-19 in hospitalized pediatric patients underġ2 years of age or weighing less than 40 kg, the FDA has granted an Emergency Use Authorization (EUA) for this unapproved use. In the United States, the Food and Drug Administration (FDA) approved Veklury on Octofor the treatment of adults and pediatric patients ≥12 years old and weighing ≥40 kg requiring hospitalization for COVID-19. Veklury has been approved or authorized for temporary use as a COVID-19 treatment in approximately 50 countries worldwide. Veklury has broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, SARS, Marburg, MERS and SARS-CoV-2, the virus that causes COVID-19. Veklury is a nucleotide analog invented by Gilead, building on more than a decade of the company’s antiviral research. Since the outset of the pandemic, we have worked closely with global health authorities to respond through the appropriate use of Veklury® (remdesivir). The program has a substantial metrics and evaluation component which is guided by the following outcome-oriented considerations: actual deployments, effectiveness in PSOs, improvement of capacities, and self-sufficiency.Gilead is focused on deploying our resources and decades of antiviral expertise to help patients and communities fighting the COVID-19 pandemic. Department of State’s Bureau of Political-Military Affairs. GPOI is funded through the Peacekeeping Operations (PKO) account, which is managed by the U.S. In Phase II, program emphasis has shifted from the direct training of peacekeepers to assisting partner country efforts to build sustainable, indigenous peacekeeping training capacity. The primary objectives for the program’s first five years (Phase I) included training 75,000 peacekeepers and building regional capacity to conduct peacekeeping operations.
Initially proposed as a five-year program (fiscal years 2005-2009), GPOI’s mandate was renewed for a second five-year period (fiscal years 2010-2014). contribution to the broader G8 Action Plan for Expanding Global Capability for Peace Support Operations, adopted at the 2004 G8 Sea Island Summit. Government-funded security assistance program intended to enhance international capacity to effectively conduct United Nations and regional peace support operations (PSOs) by building partner country capabilities to train and sustain peacekeeping proficiencies increasing the number of capable military troops and formed police units (FPUs) available for deployment and facilitating the preparation, logistical support, and deployment of military units and FPUs to PSOs. Meeting with leaders from top troop and police contributing countries “Khaan Quest” international peacekeeping training exercise
0 kommentar(er)
